Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
The objective of this study is to evaluate the efficacy and safety of Lenvatinib plus Sintilimab in patients with advanced liver cancer progressed after treatment with immune checkpoint inhibitors.
Intrahepatic Cholangiocarcinoma
DRUG: Sintilimab|DRUG: Lenvatinib
Objective Response Rate (ORR), ORR according to RECIST 1.1, max 24 months
DoR, Duration of Response, max 24 months|PFS, Progression-free survival, max 24 months|OS, Overall Survival, max 42 months|DCR, disease control rate, max 24 months|Adverse Events, Adverse event (AE)、Treatment emergent adverse event(TEAE)、Serious adverse event (SAE)., max 42 months
There is a need for options to address progressed liver cancer after the treatment of immune checkpoint inhibitors (ICIs). Sintilimab and lenvatinib are active as monotherapies liver cancer; Therefore, our aim was to evaluate the efficacy of lenvatinib combined with sintilimab in the treatment of these patients.